VTGNVistaGen Therapeutics Inc
$0.5731
$0.038
(7.10%)
Closed $0.5731
$0.0009
(0.16%)
After Hours
EarningsJun 16
Mkt Cap$21.2M
Vol958,926.00
Fundamentals
Mkt Cap
$21.2M
Volume
-
52W High
$5.14
52W Low
$0.43
PE Ratio
-0.36
Avg. Volume
871,171.26
EPS (Annual)
-$1.67
Rev/Employee
$8,526.32
Earnings
Jun 16
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Companys clinical program for fasedienol nasal spray...
Business Wire
Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates
Veeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, June 1, 2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates
HealthEquity (HQY) delivered earnings and revenue surprises of +11.57% and +0.06%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare...
Business Wire
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...
Business Wire
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest VTGN News
ViewVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business Wire
Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates
Zacks
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
PR Newswire
Advertisement|Remove ads.